On July 2, 2025, 4D Molecular Therapeutics announced the resignation of Chief Financial Officer Uneek Mehra effective July 15, alongside a workforce reduction of about 25% to save approximately $15 million annually, while preparing for accelerated Phase 3 clinical trials in wet AMD projected to yield topline data by 2027.